Scinai Reports Doubled CDMO Revenue, Strategic Recipharm Deal; Net Loss Widens to $8.3M
Summary
Scinai Immunotherapeutics reported full-year 2025 results, highlighting a doubling of CDMO revenues to $1.3 million and a strategic expansion through the acquisition of Recipharm Israel's manufacturing site and a commercial collaboration with Recipharm. This significantly enhances the company's CDMO capabilities and broadens its service offerings. However, the company posted a net loss of $8.3 million for the year, compared to a net income in 2024, and ended the year with a low cash balance of $1.8 million. This financial update follows recent SEC filings regarding a Nasdaq bid price non-compliance notice and an amendment to the PinCell acquisition option. While the operational growth and strategic partnership are positive developments, the widening net loss and tight cash position remain critical concerns for this micro-cap company, especially given its current stock price and delisting risk. Traders will closely monitor the execution of the Recipharm collaboration and the success of non-dilutive funding efforts to improve financial stability.
At the time of this announcement, SCNI was trading at $0.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $473.4K. The 52-week trading range was $0.55 to $6.18. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.